WO2008024846A3 - Brimonidine and timolol compositions - Google Patents

Brimonidine and timolol compositions Download PDF

Info

Publication number
WO2008024846A3
WO2008024846A3 PCT/US2007/076529 US2007076529W WO2008024846A3 WO 2008024846 A3 WO2008024846 A3 WO 2008024846A3 US 2007076529 W US2007076529 W US 2007076529W WO 2008024846 A3 WO2008024846 A3 WO 2008024846A3
Authority
WO
WIPO (PCT)
Prior art keywords
brimonidine
timolol
compositions
timolol compositions
disclosed
Prior art date
Application number
PCT/US2007/076529
Other languages
French (fr)
Other versions
WO2008024846A2 (en
Inventor
Rhett Schiffman
Richard Graham
Original Assignee
Allergan Inc
Rhett Schiffman
Richard Graham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, Rhett Schiffman, Richard Graham filed Critical Allergan Inc
Publication of WO2008024846A2 publication Critical patent/WO2008024846A2/en
Publication of WO2008024846A3 publication Critical patent/WO2008024846A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein are compositions containing brimonidine and timolol. Therapeutic methods and medicaments related thereto are also disclosed.
PCT/US2007/076529 2006-08-25 2007-08-22 Brimonidine and timolol compositions WO2008024846A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82352306P 2006-08-25 2006-08-25
US60/823,523 2006-08-25

Publications (2)

Publication Number Publication Date
WO2008024846A2 WO2008024846A2 (en) 2008-02-28
WO2008024846A3 true WO2008024846A3 (en) 2008-05-29

Family

ID=38779603

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/076529 WO2008024846A2 (en) 2006-08-25 2007-08-22 Brimonidine and timolol compositions

Country Status (1)

Country Link
WO (1) WO2008024846A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201818754T4 (en) * 2010-07-29 2019-01-21 Allergan Inc Brimonidine And Timolol Solutions Without Preservatives
AU2016233125A1 (en) * 2015-03-19 2017-09-14 Allergan, Inc. Fixed dose combination of bromonidine and timolol
JP2020033290A (en) * 2018-08-29 2020-03-05 興和株式会社 Aqueous composition

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211238B1 (en) * 1998-10-27 2001-04-03 Alcon Laboratories, Inc. Preservative system for topically administrable pharmaceutical compositions
WO2001070230A2 (en) * 2000-03-17 2001-09-27 Alcon, Inc. Compounds with 5-ht activity useful for controlling visual field loss
US20030199507A1 (en) * 2002-04-19 2003-10-23 Chin-Ming Chang Combination of brimonidine and timolol for topical ophthalmic use
WO2003103664A1 (en) * 2002-06-06 2003-12-18 Merck Frosst Canada & Co. 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
US6949518B1 (en) * 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
AU2005234735A1 (en) * 2000-07-14 2005-12-08 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
WO2006044232A1 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211238B1 (en) * 1998-10-27 2001-04-03 Alcon Laboratories, Inc. Preservative system for topically administrable pharmaceutical compositions
WO2001070230A2 (en) * 2000-03-17 2001-09-27 Alcon, Inc. Compounds with 5-ht activity useful for controlling visual field loss
AU2005234735A1 (en) * 2000-07-14 2005-12-08 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
US20030199507A1 (en) * 2002-04-19 2003-10-23 Chin-Ming Chang Combination of brimonidine and timolol for topical ophthalmic use
WO2003103664A1 (en) * 2002-06-06 2003-12-18 Merck Frosst Canada & Co. 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
US6949518B1 (en) * 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
WO2006044232A1 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HOMMER A B ET AL: "EFFICACY AND SAFETY OF UNOPROSTONE, DORZOLAMIDE, AND BRIMONIDINE IN ADJUNCTIVE THERAPY TO TIMOLOL IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND, US, vol. 42, no. 4, 15 March 2001 (2001-03-15), pages S554, XP009014420, ISSN: 0146-0404 *
HOYNG P F J ET AL: "PHARMACOLOGICAL THERAPY FOR GLAUCOMA", DRUGS, ADIS INTERNATIONAL LTD, AT, vol. 59, no. 3, 2000, pages 411 - 434, XP009014419, ISSN: 0012-6667 *
LARSSON L-I: "AQUEOUS HUMOR FLOW IN NORMAL HUMAN EYES TREATED WITH BRIMONIDINE AND TIMOLOL, ALONE AND IN COMBINATION", ARCHIVES OF OPHTHALMOLOGY, vol. 119, no. 4, April 2001 (2001-04-01), pages 492 - 495, XP009014425, ISSN: 0003-9950 *
SCHUMAN J S: "CLINICAL EXPERIENCE WITH BRIMONIDINE 0.2% AND TIMOLOL 0.5% IN GLAUCOMA AND OCULAR HYPERTENSION", SURVEY OF OPHTHALMOLOGY, SURVEY OF OPHTHALMOLOGY INC, vol. 41, no. SUPPL 1, November 1996 (1996-11-01), pages 27 - 37, XP009014391, ISSN: 0039-6257 *
STEWART W C: "PERSPECTIVES IN THE MEDICAL TREATMENT OF GLAUCOMA", CURRENT OPINION IN OPHTHALMOLOGY, PHILADELPHIA, PA, US, vol. 10, no. 2, April 1999 (1999-04-01), pages 99 - 108, XP000914581, ISSN: 1040-8738 *
WANG R-F ET AL: "COMPARISON OF THE OCULAR HYPOTENSIVE EFFECT OF BRIMONIDINE, DORZOLAMIDE, LATANOPROST, OR ARTIFICIAL TEARS ADDED TO TIMOLOL IN GLAUCOMATOUS MONKEY EYES", JOURNAL OF GLAUCOMA, NEW YORK, NY, US, vol. 9, no. 6, 2000, pages 458 - 462, XP009014399, ISSN: 1057-0829 *
YUKSEL N ET AL: "THE SHORT-TERM EFFECT OF ADDING BRIMONIDINE 0.2% TO TIMOLOL TREATMENT IN PATIENTS WITH OPEN-ANGLE GLACUOMA", OPHTHALMOLOGICA, KARGER, BASEL, CH, vol. 213, no. 4, 1999, pages 228 - 233, XP009014398, ISSN: 0030-3755 *

Also Published As

Publication number Publication date
WO2008024846A2 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2008014200A3 (en) Cyclosporin compositions
AU2013257508A1 (en) Pharmaceutical compositions
EP2045251A4 (en) Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses
WO2008005705A3 (en) Metal-containing formulations and methods of use
WO2007121131A3 (en) Medical devices including shape memory materials
WO2006060618A3 (en) Topical nepafenac formulations
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2009099467A3 (en) Cyclosporin compositions
WO2008027600A3 (en) Imatinib compositions
WO2007067784A3 (en) Liposomal compositions
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2009055289A3 (en) Therapeutic substituted lactams
WO2008021804A3 (en) Therapeutic amides and related compounds
WO2008021975A3 (en) Therapeutic lactams
EP2010570B8 (en) Therapy against cathepsin s
WO2007130890A3 (en) Cyclopentane-derivatives and their use as ocular hypotensive agents
WO2008024846A3 (en) Brimonidine and timolol compositions
WO2007130902A3 (en) Therapeutic cyclopentane derivatives
WO2011084781A3 (en) Oral care compositions and methods
AU2024203411A1 (en) Microimplants for ocular administration
AU2005903973A0 (en) Therapeutic compositions
AU2004900414A0 (en) Isoflavene compounds, compositions and therapeutic indications
AU2004900318A0 (en) Medicinal composition
AU2005901758A0 (en) Therapeutic Formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07841221

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07841221

Country of ref document: EP

Kind code of ref document: A2